1) Efficacy, effect
1. Acute or recurrent vaginal candidiasis
2. Oropharynx, esophagus, non-invasive bronchopulmonary infections, candiduria, and blood clots in patients with normal immune function and patients with reduced immune function.
Mucosal candidiasis, including paramucosal and chronic atrophic oral candidiasis (intraoral pain caused by dentures)
3. Including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneum, endocardium, lung, urinary system, etc.)
KEPCO systemic candidiasis
4. Patients with normal immune function and patients with reduced immune function (AIDS, organ transplant patients, or other immunosuppressed patients)
Cryptococcal meningitis (e.g., patients undergoing treatment) and cryptococcosis in other parts of the body, such as the lungs and skin
5.Maintenance therapy to prevent recurrence of cryptococcosis in AIDS patients
6. Immune system at risk of bacterial infection due to neutropenia due to cytotoxic chemotherapy, radiotherapy, or bone marrow transplantation
Prevention of fungal infections in patients with functional decline
7. Skin fungal infections, including hand and toenail mycosis, athlete's foot (tinea pedis), tinea corporis, jock itch (ring itch), tinea urticaria, and cutaneous candidiasis.
proof
2) Usage, dosage
Vaginal candidiasis: Single oral administration of 150 mg as fluconazole 2. Mucosal candidiasis: Usually administration of 50 mg once a day for 7-14 days 3. For hand and toenail mycosis, administer 150 mg once a week.
3) Packaging unit
30 capsules/bottle
4) Ingredients, content
Fluconazole 50 mg
5) Period of use
36 months from date of manufacture
6) Storage method
Airtight container, room temperature (1-30°C)
